BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, February 27, 2026
Home » Newsletters » BioWorld

BioWorld

Aug. 24, 2011

View Archived Issues

Vivus Adds $45.8M Ahead of Planned Qnexa Resubmission

Mountain View, Calif.-based Vivus Inc. priced a registered direct offering of 6.9 million shares at $6.65 each for gross proceeds of $45.8 million to boost its balance sheet and support ongoing work with obesity drug Qnexa (phentermine/topiramate), including the resubmission of a new drug application (NDA) expected next quarter. Read More

Fibrocell Brings in $22.8M to Launch Injectable laViv in U.S.

On Tuesday, Fibrocell Science Inc. appeared to swim against the tide of nervous capital markets, raising $22.8 million through a private placement of 41,409,458 shares of common stock at a purchase price of 55 cents per share. Read More

Serotonin-Activated Kinase Can Fight Amyloid Plaques

The road to developing Alzheimer's drugs has been littered with disappointments. But this week, researchers from Washington University in St. Louis published data suggesting that another class of drugs may be useful in preventing the formation of amyloid plaques: antidepressants that work via selective serotonin reuptake inhibition (SSRI). Read More

ThromboGenics' Ocriplasmin Filing on Track in Europe, U.S.

Six-month follow-up data from ThromboGenics NV's Phase III program for its ophthalmology drug Ocriplasmin (microplasmin) confirm top-line data it reported last year and keep the drug on track for a regulatory filing in the coming weeks. Read More

Stock Movers

Read More

Other News To Note

• Cel-Sci Corp., of Vienna, Va., inked a sales, marketing and distribution agreement granting IDC-GP Pharm LLC an exclusive license to cancer therapy Multikine (leukocyte interleukin injection) in Argentina and Venezuela. IDC-GP is a joint venture between two pharmaceutical entrepreneurs with expertise in registration and commercialization in South America. Under the terms, IDC-GP will be responsible for seeking regulatory approval of Multikine and commercializing the drug in its territories, with revenues split 50-50 with Cel-Sci after payment for manufacturing costs. Specific terms were not disclosed. Read More

Clinic Roundup

• PharmaNeuroBoost NV, of Alken, Belgium, received clearance from a U.S.-based institutional review board to begin a Phase III trial with PNB01 for major depression. PNB01 is a combination of the antidepressant citalopram and a low dose of the neuroleptic agent pipamperone. Read More

Popular Stories

  • Today's news in brief

    BioWorld
  • 3D rendering of skin cells and elastin with collagen layer

    First-in-class pan-inflammasome blocker for hidradenitis suppurativa

    BioWorld Science
    Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld
    Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
  • Illustration of cancer cell in crosshairs being destroyed

    RX-10616 improves radiotherapy efficacy in HNSCC

    BioWorld Science
    Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
  • Brain and virus with chromosome

    CROI 2026: Neurodegeneration, the challenge of aging with HIV

    BioWorld
    Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing